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1-, 2-, and 3-year follow-up, 6.5, 13.0, and 11.0 % of 
patients reported chest pain at less than or equal moder-
ate physical effort, respectively, without any between-
group difference. Patients treated with second-generation 
DES for TBL had somewhat higher adverse event rates 
than patients with non-TBL, but dissimilarities did not 
reach statistical significance. Up to 3-year follow-up, the 
vast majority of patients of both groups remained free 
from chest pain.
Keywords Percutaneous coronary intervention · Resolute 
stent · Xience V stent · Bifurcation treatment · Newer-
generation drug-eluting stents
Introduction
True bifurcation lesions (TBLs) are characterized by an 
advanced atherosclerotic disease burden that obstructs at 
bifurcation level both the main vessel and the side-branch. 
Percutaneous coronary interventions (PCIs) of TBL are 
often technically more challenging, require more often 
two-stent techniques [1, 2], and have previously been asso-
ciated with somewhat lower technical success rate and a 
higher restenosis risk [3–5]. Meanwhile, second-gener-
ation drug-eluting stents (DES) were developed, which 
have shown favorable outcomes in broad patient popula-
tions [6, 7]. In bifurcation lesions, the use of these contem-
porary DES reduced the incidence of restenosis as com-
pared to early DES [8–11], which might partly be related 
to an improved side-branch access [12]. Nevertheless, the 
incidence of periprocedural myocardial infarction (MI) 
is still increased in patients with bifurcated target lesions 
[13–15]. This might be related to the increased procedural 
complexity of bifurcation stenting or the atherosclerotic 
Abstract The objective of this study is to assess 3-year 
clinical outcome of patients with true bifurcation lesions 
(TBLs) versus non-true bifurcation lesions (non-TBLs) 
following treatment with second-generation drug-eluting 
stents (DES). TBLs are characterized by the obstruction 
of both main vessel and side-branch. Limited data are 
available on long-term clinical outcome following TBL 
treatment with newer-generation DES. We performed an 
explorative sub-study of the randomized TWENTE trial 
among 287 patients who had bifurcated target lesions 
with side-branches ≥2.0 mm. Patients were categorized 
into TBL (Medina classes: 1.1.1; 1.0.1; 0.1.1) versus 
non-TBL to compare long-term clinical outcome. A total 
of 116 (40.4 %) patients had TBL, while 171 (59.6 %) 
had non-TBL only. Target-lesion revascularization rates 
were similar (3.5 vs. 3.5 %; p = 1.0), and definite-or-
probable stent thrombosis rates were low (both <1.0 %). 
The target-vessel myocardial infarction (MI) rate was 
11.3 versus 5.3 % (p = 0.06), mostly driven by (peripro-
cedural) MI ≤48 h from PCI. All-cause mortality and 
cardiac death rates were 8.7 versus 3.5 % (p = 0.06) and 
3.5 versus 1.2 % (p = 0.22), respectively. The 3-year 
major adverse cardiac event rate for patients with TBL 
versus non-TBL was 20.0 versus 11.7 % (p = 0.05). At 
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disease itself, which both are generally higher in patients 
with TBL. Only few large randomized clinical trials have 
reported data on the long-term performance of second-
generation DES in bifurcated target lesions [13, 14, 16]. 
However, these studies comprised target lesions with a 
variety of bifurcation types, and clinical outcome was gen-
erally reported at the group level without specifying out-
come for patients with TBL versus non-TBL [13, 14]. As 
a consequence, long-term outcome data of patients who 
were treated with second-generation DES in TBL are of 
interest but scarce [17].
For that reason, we performed an explorative sub-study 
of the TWENTE trial [7, 18] in patients with bifurcated 
target lesions and a side-branch size of at least 2 mm, 
comparing the long-term clinical outcome of patients 
with TBL versus patients who were treated for non-TBL 
only. In addition, we analyzed the patient-reported chest 
pain to detect potential differences between patients with 
TBL versus non-TBL, and to assess the relation between 
chest pain after bifurcation stenting and hard clinical 
endpoints.
Materials and methods
Study population
The randomized TWENTE trial (ClinicalTrials.gov 
NCT01066650) enrolled 1391 patients between June 2008 
and August 2010 without any limit for target lesion length, 
reference size, and number of lesions or diseased vessels 
to be treated. The few inclusion and exclusion criteria (no 
STEMI within 48 h) and details of the study have previ-
ously been reported [7, 19]. In brief, a broad and hetero-
geneous population of PCI patients was randomized for 
treatment with the zotarolimus-eluting Resolute (Medtronic 
Inc., Santa Rosa, CA) or everolimus-eluting Xience V stent 
(Abbott Vascular, Santa Clara, CA). The TWENTE trial 
was approved by the accredited Medical Ethics Commit-
tee Twente and complied with the Declaration of Helsinki, 
and study participants provided a written informed consent. 
The 3-year clinical outcome of the TWENTE trial popula-
tion has recently been reported [18].
The present sub-study assessed patients who had bifur-
cated target lesions with a side-branch reference lumen 
diameter of ≥2.0 mm, as measured by quantitative coro-
nary angiography (QCA). Based on the lesion classifica-
tion provided by the angiographic core lab, we catego-
rized the study population into patients with at least one 
TBL that involved both main vessel and side-branch (i.e., 
Medina classes: 1.1.1; 1.0.1; 0.1.1) versus patients with 
non-TBL (i.e., Medina classes: 1.1.0; 1.0.0; 0.1.0; 0.0.1) 
only [20].
Coronary intervention
The interventional procedure was performed according 
to standard techniques, and the choice of the concomitant 
medication was based on routine institutional protocols and 
current guidelines. In bifurcated target lesions, provisional 
T-stenting of the side-branch was generally preferred [21]. 
The treatment strategy, the technique of stenting, and the 
decision to perform final kissing balloon inflations were 
left at the discretion of the operator. In general, dual anti-
platelet therapy was prescribed for 1 year.
Coronary angiographic analysis
Analysts of the angiographic core lab at Thoraxcentrum 
Twente, blinded to the stent type used, classified the lesion 
types and performed off-line quantitative coronary angi-
ography of all cases according to current standards with 
the use of dedicated edge-detection software (QAngio XA 
version 7.1; Medis, the Netherlands) [7]. Bifurcated target 
lesions, according to the definition of the present sub-study, 
were defined as lesions at junctions of a main vessel and a 
side-branch that had (after administration of intracoronary 
nitrates and before PCI) a diameter of ≥2.0 mm by QCA.
Assessment of clinical follow‑up
The follow-up procedures of the TWENTE trial have previ-
ously been reported [7, 19]. In brief, systematic laboratory 
and electrocardiographic testing were performed to iden-
tify periprocedural myocardial infarction (MI). Research 
nurses and analysts, blinded to the treatment arm, obtained 
information on clinical endpoints and chest pain by the 
use of a medical records and a medical questionnaire or, in 
the absence of a response, a telephone follow-up that was 
based on the same questions.
Patient-reported chest pain, the principal symptom of 
angina pectoris and a surrogate for myocardial ischemia, 
was classified into scores: patients with chest pain score 
0–1 were symptom free or experienced chest pain only at 
the very maximum level of physical exertion but were not 
limited in daily activities; patients with score 2 had chest 
pain at moderate physical effort (during moderate/normal 
daily activities); and patients with score 3 had chest pain at 
mild physical effort or even at rest [22].
Definition of clinical endpoints
Clinical endpoints were defined according to the Aca-
demic Research Consortium (ARC) [23, 24]. Cardiac 
death was defined as any death due to proximate cardiac 
cause (e.g., MI, low-output failure, fatal arrhythmia). MI 
was defined by any creatine kinase concentration of more 
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than double the upper limit of normal with elevated values 
of a confirmatory cardiac biomarker (creatine kinase MB 
fraction or troponin), based on the updated ARC defini-
tion of MI. Periprocedural MI (PMI) was defined as tar-
get-vessel-related MI within 48 h after PCI [23, 24]. The 
cardiac markers were systematically assessed with subse-
quent serial measurements in case of relevant elevation or 
complaints. Stent thrombosis was defined according to the 
ARC as definite or probable. Target-lesion failure (TLF) 
was defined as a composite of cardiac death, target-vessel-
related MI, or clinically indicated target-lesion revascu-
larization (TLR), and major adverse cardiac event (MACE) 
was defined as a composite of all-cause mortality, any MI, 
emergent coronary bypass surgery, or TLR [7].
Clinical event adjudication was performed by inde-
pendent, external clinical event committees, organized 
by independent clinical research organizations (Cardi-
alysis, Rotterdam, the Netherlands; and Diagram, Zwolle, 
the Netherlands). The TWENTE trial is an investigator-
initiated study, supported by equal unrestricted research 
grants from Abbott Vascular and Medtronic. The authors 
are solely responsible for the study design, conducting the 
study, statistical analysis, and reporting of outcomes.
Statistical analysis
Continuous variables were expressed as mean ± stand-
ard deviation (SD), and categorical data were presented 
as numbers and percentages. Baseline characteristics were 
compared using Chi-square test or Fisher’s exact test for 
categorical variables and Student’s t test for continuous var-
iables. The time to clinical endpoint was assessed accord-
ing to the Kaplan–Meier method, and the log-rank test was 
applied to compare the incidence of MACE in patients with 
TBL versus non-TBL. Confidence intervals and p values 
were two sided. Analyses were performed using SPSS 15.0 
(SPSS Inc., Chicago, IL, USA). p values <0.05 were con-
sidered significant.
Results
Demographics and cardiovascular risk profile 
of patients
A total of 287 (20.6 %) patients of all 1391 TWENTE 
trial participants had bifurcated target lesions with side-
branches ≥2.0 mm. Based on the Medina classification 
of the bifurcation lesion, patients were categorized into 
the TBL (n = 116, 40.4 %) versus the non-TBL groups 
(n = 171, 59.6 %). Patients of the two groups did not differ 
in demographics and cardiovascular risk profile (Table 1).
Lesion characteristics and interventional procedure
The lesion characteristics (other than the Medina class) 
were similar for both groups, with the only exception being 
a slightly smaller side-branch lumen diameter in the TBL 
group (2.3 ± 0.3 vs. 2.4 ± 0.4 mm; p = 0.01) (Table 2). 
The rate of stent postdilatation was high and similar in 
Table 1  Characteristics of patients with true versus non-true bifurcation lesions with side-branches ≥2 mm
Values are n (%) or mean (±SD). Patients of the TBL group were treated for at least one TBL
CABG coronary artery bypass grafting, CAD coronary artery disease, MI myocardial infarction, PCI percutaneous coronary intervention, TBL 
true bifurcation lesion
True bifurcation lesion (TBL) group
(n = 116)
Non-true bifurcation lesion (non-TBL) group
(n = 171)
p
Age (years) 65.4 ± 10.6 64.0 ± 10.4 0.26
Female gender 30 (25.9) 44 (25.7) 0.98
Diabetes mellitus 24 (20.7) 32 (18.7) 0.68
Arterial hypertension 64 (55.2) 90 (52.6) 0.67
Hypercholesterolemia 60 (54.1) 87 (51.5) 0.67
Current smoker 33 (28.4) 42 (24.6) 0.46
Family history of CAD 53 (45.7) 90 (52.6) 0.25
Previous MI 41 (35.3) 48 (28.1) 0.19
Previous PCI 22 (19.0) 29 (17.0) 0.66
Previous CABG 12 (10.3) 11 (6.4) 0.23
Clinical syndrome 0.97
 Stable angina pectoris 55 (47.4) 81 (47.4)
 Unstable angina 31 (26.7) 44 (25.7)
 Non-ST elevation MI 30 (25.9) 46 (27.9)
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both groups (95.2 vs. 94.2 %; p = 0.57). However, as may 
be expected, in patients with TBL a two-stent bifurcation 
approach was more often performed (41.4 vs. 11.1 %; 
p < 0.01), and the total number of stents implanted and the 
rate of final kissing balloon inflation were higher in this 
group (Table 2). If two-stent technique was applied, T-stent-
ing (61.2 %) was generally preferred above (mini-)crush 
(20.9 %), culotte (10.3 %), and other two-stent approaches 
(7.5 %). Final kissing balloon inflation was performed in 
36.4 % of patients treated with the single-stent approach 
and in 77.6 % of patients treated with two-stent techniques.
Long‑term clinical outcome
Three-year follow-up was available in 286 (99.7 %) 
patients; 1 patient withdrew consent during follow-up. The 
TLR rate was low in both groups (3.5 vs. 3.5 %; p = 1.0) 
(Table 3). The rates of definite-or-probable stent thrombosis 
Table 2  Lesion and procedural characteristics of patients with true versus non-true bifurcation lesions
Values are n (%) or mean (±SD) unless otherwise stated. In case of multiple target lesions with side-branches ≥2 mm, quantitative coronary 
angiographic data of the lesion with the most severe lumen diameter obstruction are presented. In case of multiple bifurcated target lesions, a 
two-stent approach was scored if applied in at least one target lesion
PCI percutaneous coronary intervention, SB side-branch, TBL true bifurcation lesion
True bifurcation lesion (TBL) group
(n = 116)
Non-true bifurcation lesion (non-TBL) group
(n = 171)
p
Lesion characteristics
De novo lesions 99 (85.3) 154 (90.1) 0.23
Severe calcification 21 (18.1) 35 (20.5) 0.62
At least one aorto-ostial lesion 8 (6.9) 15 (8.8) 0.57
Treated coronary vessels
 Left main 11 (9.5) 19 (11.1) 0.66
 Right coronary artery 17 (14.7) 36 (21.1) 0.17
 Left anterior descending artery 91 (78.4) 124 (72.5) 0.26
 Circumflex artery 41 (35.3) 62 (36.3) 0.87
Medina classification <0.01
 0.1.1 39 (33.6) 0
 1.0.1 18 (15.5) 0
 1.1.1 59 (50.9) 0
 0.0.1 0 25 (14.6)
 0.1.0 0 51 (29.8)
 1.0.0 0 44 (25.7)
 1.1.0 0 51 (29.8)
Bifurcation angle (°) 55.7 ± 22.1 62.1 ± 41.0 0.14
Longest lesion length (mm) 20.1 ± 11.1 20.1 ± 12.3 0.78
Degree of stenosis before PCI (%) 67.5 ± 13.3 67.1 ± 13.3 0.76
Residual in-stent stenosis post PCI (%) 15.2 ± 6.2 14.3 ± 6.2 0.25
Side-branch characteristics
 Lumen diameter SB before PCI (mm) 2.3 ± 0.3 2.4 ± 0.4 0.01
 Degree of SB stenosis before PCI (%) 62.8 ± 13.0 65.4 ± 18.8 0.40
 Longest SB lesion length (mm) 10.0 ± 6.3 10.8 ± 8.1 0.58
Procedural characteristics
Number of stents per patient 2.6 ± 1.4 2.2 ± 1.2 0.01
Total stent length per patient (mm) 50.0 ± 29.8 43.4 ± 27.4 0.06
Predilatation 90 (77.6) 115 (67.3) 0.06
Stent postdilatation 111 (95.2) 161 (94.2) 0.57
Final kissing balloon inflation 65 (56.0) 67 (39.2) <0.01
Single- versus two-stent approach <0.01
 Single-stent approach 68 (58.6) 152 (88.9)
 Two-stent approach 48 (41.4) 19 (11.1)
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were very low; a single definite stent thrombosis occurred 
after 17 months in a patient with TBL. The target-vessel 
MI rate was 11.3 versus 5.3 % (p = 0.06), mostly driven 
by (periprocedural) MI ≤48 h from PCI (9.6 vs. 4.7 %; 
p = 0.10). All-cause mortality and cardiac death rates were 
8.7 vs. 3.5 % (p = 0.06) and 3.5 vs. 1.2 % (p = 0.22), 
respectively.
The 3-year MACE rate for patients with TBL versus 
non-TBL was 20.0 vs. 11.7 % (p = 0.05), respectively. A 
Kaplan–Meier analysis of MACE in Fig. 1 shows the time-
to-event curves, which reflect a numerically dissimilar 
incidence of periprocedural events and, during the second 
year of follow-up, a somewhat further diverging course. 
Landmark analysis revealed that during the first 48 h from 
stenting and from 48 h until 3-year follow-up, MACE was 
not significantly different between patients treated for TBL 
versus non-TBL (9.6 vs. 4.7 %, pLogrank = 0.12, and 11.4 
vs. 7.4 %, pLogrank = 0.26, respectively) (Fig. 2). All but 
2 MACE (related to additional non-bifurcated target lesions 
in patients with multivessel treatment) were related to the 
bifurcated target lesions.
Chest pain at follow‑up, and adverse events 
during consecutive time intervals
At 30-day, 1-, 2-, and 3-year follow-up, overall 3.0, 6.5, 
13.0, and 11.0 % of patients reported chest pain at ≤ mod-
erate physical effort. The percentages of patients with 
clinically relevant chest pain at 30-day, 1-, 2-, and 3-year 
follow-up are presented in Fig. 3. There was no significant 
between-group difference in chest pain, and the vast major-
ity of these patients were free from chest pain or had pain 
only occasionally at the very maximum level of physical 
Table 3  Three-year clinical outcome of patients with true versus non-true bifurcation lesions
Values are n (%)
PCI percutaneous coronary intervention
a Due to one withdrawal of consent in the true bifurcation lesion (TBL) group, the number of patients with 3-year follow-up is one lower as 
compared to baseline. Target-lesion failure (TLF) is a composite of cardiac death, target-vessel-related myocardial infarction, or clinically indi-
cated target-lesion revascularization (TLR); major adverse cardiac event (MACE) is a composite endpoint of all-cause mortality, any myocardial 
infarction, emergent coronary bypass surgery, or TLR; periprocedural myocardial infarctions occurred during the first 48 h after an index proce-
dure
True bifurcation lesion (TBL) group
(n = 115)a
Non-true bifurcation lesion (non-TBL) group
(n = 171)
p
Adverse clinical events
All-cause mortality 10 (8.7) 6 (3.5) 0.06
Cardiac death 4 (3.5) 2 (1.2) 0.22
Any myocardial infarction 13 (11.3) 9 (5.3) 0.06
Target-vessel-related myocardial infarction 13 (11.3) 9 (5.3) 0.06
Periprocedural myocardial infarction 11 (9.6) 8 (4.7) 0.10
Myocardial infarction >48 h post PCI 2 (1.7) 1 (0.6) 0.57
Target-lesion revascularization (TLR) 4 (3.5) 6 (3.5) 1.00
Emergent coronary bypass surgery 0 0
Definite-or-probable stent thrombosis 1 (0.9) 0 0.40
Composite clinical endpoints
Target-lesion failure (TLF) 19 (16.5) 16 (9.4) 0.07
Major adverse cardiac events (MACE) 23 (20.0) 20 (11.7) 0.05
Fig. 1  Cumulative incidence of MACE following PCI with second-
generation DES in patients of the true versus non-true bifurcation 
lesion groups. All patients had been treated for at least one bifurcated 
target lesion with a side-branch ≥2 mm. DES drug-eluting stents, 
MACE major adverse cardiac event, a composite endpoint of all-
cause mortality, any myocardial infarction, emergent coronary bypass 
surgery, and target-lesion revascularization, PCI percutaneous coro-
nary intervention
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exertion. MACE and coronary revascularization during 
subsequent time intervals were rare in both, patients with 
and without chest pain.
Discussion
In the present study, we assessed the long-term outcome 
of 287 patients with bifurcated target lesions and side-
branches ≥2 mm from the TWENTE trial, who were 
treated with second-generation DES. The 3-year TLR 
rate did not differ between 115 patients with TBL ver-
sus 171 patients with non-TBL only (3.5 % both); and in 
both patient groups the risk of definite-or-probable stent 
thrombosis was very low (both <1.0 %). During the 3-year 
follow-up of the present study, similar in both groups, the 
vast majority of patients were free from chest pain. The 
MACE rates of patients with TBL and non-TBL were 20 
and 11.7 %, respectively. This numerical but non-signifi-
cant dissimilarity in MACE (p = 0.05) was related to the 
incidence of all-cause mortality as well as MI; the latter 
occurred mostly within 48 h from stenting (i.e., periproce-
dural MI).
Bifurcation treatment with second‑generation DES
Second-generation DES have only been used in a few 
prospective studies that investigated clinical outcome fol-
lowing PCI for bifurcation lesions [9, 25–28]. In the 
Z-SEAside study, patients with bifurcation lesions who 
were treated with the Resolute stent showed a lower rate 
of a procedure-related composite endpoint than patients 
who were treated with the first-generation sirolimus-elut-
ing stent (n = 75, each) [25]; and a multicenter registry of 
180 patients who were treated with Resolute in bifurcated 
lesions also showed a low 9-month MACE rate [28]. Long-
term outcome data from dedicated bifurcation studies with 
second-generation DES are scarce [17]. A recent pooled 
analysis of the 3-year clinical outcome of the randomized 
SEAside and CORpal studies [9, 10] showed a favorable 
MACE rate beyond 1 year in patients treated with Xience V 
stent as compared to the first-generation sirolimus-eluting 
stent [16]. Moreover, a retrospective study in 237 patients 
found acceptable clinical outcomes up to 2 years after 
the implantation of Xience V and Resolute in bifurcation 
lesions [29]. Recent sub-studies of the RESOLUTE All 
Comers, TWENTE, and DUTCH PEERS trials revealed 
similar and favorable 2- and 3-year clinical outcomes for 
patients who were treated with newer-generation DES for 
bifurcated versus non-bifurcated target lesions [13–15].
True bifurcation stenting
Percutaneous interventions of TBL, which are character-
ized by an advanced atherosclerotic disease burden that 
obstructs the main vessel and the side-branch, are often 
technically more demanding, require more frequently com-
plex techniques that involve the implantation of 2 stents, 
and were previously associated with a higher restenosis 
risk [1, 3–5]. Besides the increased procedural complexity 
of stenting, a more diffuse distribution of atherosclerotic 
plaque and a more advanced disease stage may account for 
an increased risk of adverse events in patients treated for 
TBL.
So far, only few studies address TBL treatment with 
second-generation DES. A small randomized study in 69 
patients revealed similar angiographic and clinical 9-month 
results after treatment of (predominantly true) bifurca-
tion lesions with Xience V stents, using a simple versus a 
complex strategy [26]. These findings were confirmed by 
Fig. 2  Landmark analysis of MACE at 2 days. MACE major adverse 
cardiac event, a composite endpoint of all-cause mortality, any myo-
cardial infarction, emergent coronary artery bypass surgery, and tar-
get-lesion revascularization
Fig. 3  Clinically relevant chest pain at four time points of follow-
up. Clinically relevant chest pain was defined as chest pain at moder-
ate physical effort (during moderate/normal daily activities), at mild 
physical effort, or even at rest
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a retrospective study in 319 patients, who were treated 
with Xience for TBL, showing favorable angiographic and 
1-year clinical outcomes in patients treated with a 2-stent 
technique [30]. Despite the overall favorable outcome of 
bifurcation treatment with second-generation DES, there 
has been a higher incidence of periprocedural MI [13, 14, 
27].
Our present study suggests that the risk of periproce-
dural MI might be higher in TBL. This could be related to 
the often-greater atherosclerotic burden in TBL, which may 
lead to more plaque displacement (with an occlusion of 
small side-branches) and/or distal embolization of athero-
thrombotic material during stenting [31]. While there is 
still an ongoing debate on the clinical impact of periproce-
dural MI [32, 33], it has recently been shown that peripro-
cedural MI after treatment of TBL with a wide variety of 
DES types was associated with a significant increase in 
1-year mortality [34].
In the present study, both 3-year mortality (8.7 vs. 3.5 %, 
p = 0.06) and MACE rate (20.0 vs. 11.7 %, p = 0.05) were, 
albeit statistically non-significant, numerically higher in 
patients with TBL versus non-TBL. While a play of chance 
cannot be excluded, this numeric difference might also be 
related to a more diffuse distribution of atherosclerosis that 
cannot be explained from patient demographics and cardi-
ovascular risk factors, which did not differ between both, 
patients with TBL and non-TBL in the present study.
Chest pain during follow‑up of patients with bifurcation 
stenting
Chest pain following successful PCI with DES is clini-
cally and economically relevant, as it often initiates the 
consultation of a general practitioner or cardiologist with 
further cardiac assessment [35]. While there is growing 
interest in this issue [36], most recent studies on bifur-
cation treatment with DES have focused on device-ori-
ented clinical endpoints [5]. Overall, data on chest pain 
in patients treated with second-generation DES are scarce 
[5, 36]. The randomized DUTCH PEERS trial found no 
difference in chest pain between two DES at 1- and 2-year 
follow-up [22].
In the present study, we documented, similar to the 
DUTCH PEERS trial, patient-reported chest pain in rela-
tion to the patient’s individual range of physical activities. 
The majority of patients treated for TBL or non-TBL were 
free from clinically relevant chest pain. This symptom will 
generally determine whether a patient seeks further medi-
cal assessment. The absence of chest pain in the majority of 
our patients is supported by previous studies in bifurcation 
lesions, which showed that provisional stenting of the main 
branch generally does not result in a significant reduction 
in fractional flow reserve of the jailed side-branch, which 
means that there is usually no ischemia in the myocardium 
subtended by the jailed branch [37–39].
Study limitations
Due to the explorative nature and the sample size of the 
present study, findings should be considered hypoth-
esis generating. The comparison of findings from differ-
ent bifurcation stent studies is hampered by the fact that 
there is no uniformity in the minimum size of (relevant) 
side-branches and no general consent on whether to deter-
mine side-branch size visually or per QCA [4, 10, 13, 14, 
25, 40]. Bifurcation lesions with side-branches ≥2 mm, 
as addressed in our present study, were also examined in 
the Z-SEAside and the SEAside studies [9, 25]. Recently, 
advanced, user-friendly three-dimensional reconstruction 
and analysis software for bifurcation lesions has become 
available [41], but such software was not available at the 
time of angiographic analysis of the TWENTE trial.
Conclusions
Patients treated with second-generation DES for TBL had 
somewhat higher adverse event rates than patients with 
non-TBL, but dissimilarities did not reach statistical signif-
icance. Up to 3-year follow-up, the vast majority of patients 
of both groups remained free from chest pain.
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